# Induction of LGR5 by H<sub>2</sub>O<sub>2</sub> treatment is associated with cell proliferation via the JNK signaling pathway in colon cancer cells

SUNG-HEE KIM<sup>1</sup>, KYUNG-HEE KIM<sup>2</sup>, BYONG-CHUL YOO<sup>2</sup> and JA-LOK  $KU^1$ 

<sup>1</sup>Laboratory of Cell Biology, Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744; <sup>2</sup>Colorectal Cancer Branch, Research Institute, National Cancer Center, Goyang, Gyeonggi 411-764, Republic of Korea

Received May 18, 2012; Accepted July 13, 2012

DOI: 10.3892/ijo.2012.1596

Abstract. Recently, the leucine-rich repeat G protein-coupled receptor 5 (LGR5/GPR49) was identified as a potential marker of intestinal stem cells in human. The LGR5 is known as a Wnt signaling target gene, and its expression pattern is related with  $\beta$ -catenin mutation. H<sub>2</sub>O<sub>2</sub> is a member of reactive oxygen species (ROS) and regulates metabolism, aging, apoptosis and the intensity of growth factor signaling. In addition, it acts as a negative or positive regulator of Wnt signaling. However, the effect of  $H_2O_2$  on Wnt signaling and its target gene LGR5 is not clear. In this study, we investigated the effects of ROS on cancer stem cells, in colorectal cancer cells. Colorectal cancer cells were treated with exogenous H<sub>2</sub>O<sub>2</sub>, after which cellular responses and the expression of LGR5 were examined. In SNU-C2A cells, proliferation increased following treatment with 50-300  $\mu$ M of H<sub>2</sub>O<sub>2</sub>, whereas cell viability significantly decreased after treatment with 600-900  $\mu$ M of H<sub>2</sub>O<sub>2</sub>. Expression of heme oxygenase (HO)-1 and jun, which aid in the reduction of oxidative stress, were induced in the low dose H2O2-treated SNU-C2A cells. The LGR5 expression level was significantly increased following 50-300  $\mu$ M H<sub>2</sub>O<sub>2</sub> treatment; in addition,  $\beta$ -catenin was increased in H<sub>2</sub>O<sub>2</sub>-treated colon cancer cells. However, the increased  $\beta$ -catenin was detected not in the nucleus but in the cytoplasm, which means that  $\beta$ -catenin was stabilized in the cytoplasm and not translocated into the nucleus where it could function as a transcription factor for the expression of LGR5. In addition, there was no direct interaction between LGR5 and  $\beta$ -catenin. In this study, we found that LGR5 expression increased when cancer cells were treated with a low dose of H<sub>2</sub>O<sub>2</sub>. Our results indicate that the LGR5 increase resulted via activation of the JNK signaling pathway. The induction of LGR5 expression influenced cell proliferation in colorectal cancer cells.

E-mail: kujalok@snu.ac.kr

## Introduction

In a recent study, the leucine-rich repeat G protein-coupled receptor 5 (LGR5, also known as GPR49) was identified as a potential marker of intestinal stem cells in human (1-3). LGR5 is expressed mainly in crypt base columnar (CBC) cells at the bottom of intestinal crypts and it is a markers for both cancer and normal intestinal stem cells (1). Cancer stem cells (CSCs) are a small population of cancer cells that have the ability to affect tumor initiation, differentiation and metastasis. The selfrenewal and differentiation capabilities of CSCs are similar to those of normal embryonic or adult stem cells (4,5). For isolation of CSCs, some cell surface markers, so-called cancer stem cell markers, can be used. In the intestine, functional stem cells are located at the bottom of the crypts, especially at the +4 position (1-3), and they can be isolated and studied via molecular markers such as CD34, CD44, CD133, and LGR5 (6-8). CSCs play an important role in cancer recurrence after radio- or chemotherapy (9-11), and CSC-mediated resistance to radiation and chemotherapeutic agents is influenced by the cellular level of reactive oxygen species (ROS) (11,12).

Many ROS, including  $O_2^-$ , OH<sup>-</sup>, and  $H_2O_2$ , are produced by physiological intracellular reactions and function not only as a byproduct of cellular metabolisms but also as a mediator of cell signaling pathways (13).

Diehn *et al* demonstrated that CSCs in breast and head/neck tumors have lower ROS levels and higher expression levels of antioxidant genes or proteins, compared to levels in nontumorigenic progeny, which were similar to levels in normal stem cells (12). However, the effects of ROS on CSCs have not been fully described.

The above-mentioned LGR5 is a Wnt target gene and its expression pattern has been related to  $\beta$ -catenin mutation (2,14,15). It has been shown that H<sub>2</sub>O<sub>2</sub> can inhibit the Wnt/ $\beta$ -catenin signaling pathway through decreases in the amount of nuclear  $\beta$ -catenin and Tcf/Lef dependent transcription (16). In contrast, Funato *et al* showed that H<sub>2</sub>O<sub>2</sub> induces  $\beta$ -catenin stabilization and increases the expression of endogenous Wnt target genes (17). Despite these studies, little is known about the effect of H<sub>2</sub>O<sub>2</sub> on the Wnt/ $\beta$ -catenin signaling pathway.

The purpose of this study is to reveal the effects of ROS on various aspects of CSCs, in colorectal cancer cells. To study this, colorectal cancer cells were treated with exogenous  $H_2O_2$ ,

*Correspondence to:* Dr Ja-Lok Ku, Laboratory of Cell Biology, Cancer Research Institute, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Republic of Korea

Key words: leucine-rich repeat G protein-coupled receptor 5,  $H_2O_2$ , heme oxygenase-1, JNK signaling,  $\beta$ -catenin

| Table I. Sequences of specific primers used in the study |                   |                |         |         |            |
|--|-------------------|----------------|---------|---------|------------|
| · · · ·  | Table I. Sequence | es of specific | primers | used in | the study. |

| Gene      |                    | Primer sequence   | Size (bp) | Refs. |
|-----------|--------------------|---|-----------|-------|
| h LGR5    | Forward<br>Reverse | 5'-AGGATCTGGTGAGCCTGAGAA-3'<br>5'-CATAAGTGATGCTGGAGCTGGTAA-3' | 151       | (25)  |
| β-catenin | Forward<br>Reverse | 5'-TCTTGGCTATTACGACAG-3'<br>5'-CCTCTATACCACCCACTT-3'          | 459       | (16)  |
| HO-1      | Forward<br>Reverse | 5'-GCTCAACATCCAGCTCTTTGAGG-3'<br>5'-GACAAAGTTCATGGCCCTGGGA-3' | 282       | -     |
| β-actin   | Forward<br>Reverse | 5'-GACCACACCTTCTACAATGAG-3'<br>5'-GCATACCCCTCGTAGATGGG-3'     | 301       | (17)  |

and then examined for expression of the CSC marker, LGR5, and for cellular responses.

#### Materials and methods

*Cell culture*. Thirty of the 32 human colorectal cancer cell lines were maintained in RPMI-1640 media. The CACO-2 cell line was maintained in minimum essential medium and the WiDr cells were maintained in Dulbecco's modified Eagle's medium (cells obtained from Korean Cell line Bank, Seoul, Korea). All media were supplemented with 10% fetal bovine serum (FBS), 100 U/ml of penicillin, and 0.1 mg/ml of streptomycin. Cells were maintained in humidified incubators at 37°C, with an atmosphere of 5% CO<sub>2</sub> and 95% air.

*Cell proliferation assay by MTT*. Cell proliferation was analyzed by using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide] (Sigma Chemical Co.) assay.

Initially,  $3x10^6$  cells were seeded on 96-well plates and cultured for 1 day. Subsequently, media containing 50-900  $\mu$ M of H<sub>2</sub>O<sub>2</sub> were added to the plates and the cells incubated for 24 h before being treated with 50  $\mu$ l of MTT solution for 4 h at 37°C. Absorbance at 540 nm was measured by an ELISA reader (Molecular Devices Co., CA, USA).

Total RNA extraction, cDNA synthesis and reverse transcriptase-PCR (RT-PCR). Total RNA was isolated by using easy-BLUE<sup>™</sup> kits (Intron Biotechnology, Gyeonggi, Korea). For cDNA synthesis, 2  $\mu$ g of total RNA were combined with a random primer, dNTP, and 200 U of Superscript II™ reverse transcriptase (Invitrogen, Carlsbad, CA, USA) in a final volume of 20  $\mu$ l. The mixture incubated for 60 min at 42°C, after that incubated for 15 min at 70°C for denaturation. Next, 80 µl of distilled water was added to the reverse-transcription reaction mixture. PCR was performed to obtain mRNA expression data. The prepared 15  $\mu$ l PCR mixtures included 1  $\mu$ l of cDNA, 10X buffer, 2.5 mM of dNTP, 0.1 pM of primers and 1 U of Taq DNA polymerase (Intron Biotechnology). PCR amplification was conducted using the described primer sets (Table I). The β-actin was used as an endogenous reference for the normalization of expression levels. The following PCR conditions were used: initial denaturation for 5 min at 94°C, cycling at 94°C (30 sec), 55°C (30 sec), and 72°C (30 sec) for 35 cycles, with final elongation for 7 min at 72°C. PCR was performed in a thermal cycler (PCR System 9700, Applied Biosystems, Foster City, CA, USA). The PCR products were divided in 2% agarose gel stained with ethidium bromide.

Treatment of hydrogen peroxide. For exogenous  $H_2O_2$  treatment, cells were seeded in 75 cm<sup>2</sup> culture flasks at a rate of  $0.5x10^6$  cells per flask. After 1 day, the cells treated with 0, 50, 100, 150, 300, 600, or 900  $\mu$ M of  $H_2O_2$  (Sigma Chemical Co.) for 24 h. Subsequently, the cells were harvested for protein, RNA isolation, and cell cycle analysis.

Western blotting. For protein analysis, harvested cells were washed in PBS, suspended in Pro-Prep<sup>™</sup> kits (Intron Biotechnology) and placed on ice for 30 min. After centrifuging at 13,000 x g for 30 min at 4°C, the supernatant was collected. Protein quantitative analysis was accomplished by using Bradford's method using BSA (Sigma Chemical Co.). Protein  $(20 \ \mu g)$  and 4X SDS sample buffer (Invitrogen) mixtures were boiled at 95°C for 5 min and loaded on 4-12% Bis-Tris gel (Invitrogen) at 100 V for 3 h. Proteins were transferred to a PVDF membrane (Invitrogen) by electroblotting at a constant 270 mA current for 2 h. For membrane blocking, the membrane was incubated for 1 h at room temperature in 1.5% non-fat dry milk and 0.5% Tween-20 TBS buffer containing 1 mM of MgCl<sub>2</sub>. Primary antibodies against hLGR5 (GPR49) (Abcam, Cambridge, UK) (1:500), heme oxygenase-1 (Abcam) (1:1,000), jun (BD, New Jersey, USA) (1:1,000), PARP (BD) (1:1,000), β-catenin (Abcam) (1:2,000), HSP60 (Abcam) (1:1,000), and Lamin-B (Abcam) (1:1,000) were incubated overnight at 4°C. For secondary antibody incubation, peroxidase conjugated mouse or rabbit IgG antibody (Jackson Immunoresearch, Baltimore, MD, USA) was diluted 1:5,000. After incubation at room temperature for 1 h, a chemiluminescent working solution, WESTZOL<sup>™</sup> (Intron Biotechnology) was decanted to the membrane. The membrane was then covered with a thin plastic wrap and exposed to Fuji RX film for 1-60 min.

*Cell cycle analysis.* For cell cycle distribution analysis, cells treated with  $H_2O_2$  were fixed overnight in 70% ethanol at -20°C. Subsequently, cellular DNA was stained with 100  $\mu$ g/ml of propidium iodide (PI) (Sigma Chemical Co.) for 30 min on ice. After staining, cells were subjected to fluorescence-activated

cell sorter (FACs CantoII<sup>™</sup>, BD, NJ, USA) analysis of DNA content to determine the percentage of the cells in different cell phases and in apoptosis.

Immunocytochemical staining. For visual cell examination, 0.5x10<sup>5</sup> cells were grown on cover slips in 12-well culture plates. After 1 day, the cell-covered slips were treated with  $H_2O_2$  for 24 h, then rinsed briefly in PBS and fixed with 3.7% formaldehyde (Sigma Chemical Co.) in PBS for 15 min at room temperature. For permeabilization, samples were incubated for 10 min with 0.25% Triton X-100 (Merck, Darmstadt, Germany) in PBS at room temperature. Samples were then incubated with 1% BSA (Invitrogen) in PBS-T for 30 min at room temperature for blocking, and then treated with 1:1,000 diluted LGR5 and  $\beta$ -catenin primary antibody in PBS-T overnight at 4°C. Subsequently, the samples were rinsed and incubated with 1:500 diluted goat anti-rabbit secondary antibody for 2 h at room temperature in the dark. 4',6-diamidino-3-phenylindole dihydrochloride hydrate (DAPI, 100  $\mu$ g/ml) (Sigma Chemical Co.) was used for counter staining. Cells were visualized using a Pascal confocal microscope (Carl Zeiss, Oberkochen, Germany).

*Preparation of nuclear extraction.* The cells were removed from the culture flask by scraping and washed in PBS. For cytoplasmic fraction collection, cells were resuspended in 500  $\mu$ l of 1X hypotonic buffer and 25  $\mu$ l of detergent (Active Motif, Shinjuku, Japan). Following centrifuging at 14,000 x g for 30 sec at 4°C, the supernatant (the cytoplasmic fraction), to a new tube. Remaining nuclear pellet was resuspended in 50  $\mu$ l of complete lysis buffer (Active Motif) and incubated for 30 min on ice. Following which it was centrifuged for 10 min at 14,000 x g at 4°C. The supernatant (the nuclear fraction), was then transferred to a new tube.

Co-immunoprecipitation of LGR5. LGR5 primary antibody (5  $\mu$ g) was added to the microcentrifuge tube that contained the SNU-C2A lysate (200  $\mu$ g); the mixture was then incubated overnight at 4°C. Subsequently 20  $\mu$ l of anti-rabbit IgG beads (eBioscience, Iceland, UK) were added and the mixture incubated for 1 h at 4°C. Next, the tube was centrifuged for 1 min at 10,000 x g at 4°C. The supernatant was then removed and the bead pellet resuspended using Pro-Prep<sup>TM</sup> (Intron Biotechnology). After washing, add 20  $\mu$ l of 2X SDS sample buffer (Invitrogen) were added and the mixture boiled at 95°C for 10 min. While avoiding loading of anti-rabbit IgG beads, the supernatant was loaded on to 4-12% Bis-Tris gel.

## Results

Increased apoptotic cell death at high dose of  $H_2O_2$ . For the analysis of expression level of LGR5, we investigated expression in 32 human colorectal cancer cell lines by RT-PCR. LGR5 was highly expressed in most of cell lines (29/32 cell lines; 90.63%) and expressed at a low level in 3 cell lines (SNU-503, SNU-C2A, and SNU-C5) (Fig. 1). To determine whether ROS treatment would affects the cell proliferation in SNU-C2A, which has wild-type  $\beta$ -catenin (18), SNU-C2A cells were treated with 50, 100, 150, 300, 600, or 900  $\mu$ M of H<sub>2</sub>O<sub>2</sub> and incubated for 24 h. As shown in Fig. 2A, the number



Figure 1. Analysis of LGR5 expression level. LGR5 expression levels in 32 human colorectal cancer cell lines were analyzed by RT-PCR. Each sample was normalized to  $\beta$ -actin levels.



Figure 2. Increased cell proliferation following low dose  $H_2O_2$ . (A), Cell proliferation assay results using the MTT method. SNU-C2A cells treated with 50, 100, 150, 300, 600, or 900  $\mu$ M of  $H_2O_2$  for 24 h before determining cell viability. To validate the data, the experiment was repeated three times (\*p<0.05). (B), Cell cycles analyzed by using fluorescence-activated cell sorter (FACs). Cells treated with  $H_2O_2$  were fixed in 70% ethanol before staining DNA with 100  $\mu$ g/ml of PI.

of SNU-C2A cells increased when treated with a low dose of  $H_2O_2$ , but the relationship dosage and cell increase had no significant correlation. However, SNU-C2A cell viability was significantly decreased when treated with 600 or 900  $\mu$ M of  $H_2O_2$  (p<0.005). Park *et al* suggested that a low level of  $H_2O_2$ promotes cancer cell proliferation, compared to that in the control cells, while at a higher  $H_2O_2$  concentration the cancer cells exhibited an 80% growth inhibition with apoptosis triggered via activation of the AMP-activated protein kinase (AMPK) pathway (19). Here, since SNU-C2A cell viability increased at the low concentration of  $H_2O_2$ , the percentage of



Figure 3. Western blotting of PARP for apoptosis assessment. Intact PARP was identified as a 116-kDa band (upper band). During apoptosis, PARP is cleaved from the intact form into 85 kDa (lower band). When treated with  $H_2O_2$ , the cleaved PARP form increased in dose-dependent manner.

subG1, G1, S, and G2/M cell cycle phases were determined by FACs in order to investigate the effect of  $H_2O_2$  on the cell cycle. As shown in Fig. 2B, the percentage of cells in the G1 stage increased under treatment with 50-300  $\mu$ M of  $H_2O_2$ , which indicates that the cell cycle was arrested to evade cell death by the ROS. However, at higher  $H_2O_2$  concentration the percentage of cells in the G2/M stage decreased, and that in the subG1 stage increased. The increase in the subG1 stage is mediated through cell death at the higher concentration of  $H_2O_2$ .

As PARP [poly(ADP-ribose) polymerase] cleavage is considered a marker of apoptosis (20), we performed western blotting to detect the presence of PARP cleavage. The level of the 85 kDa cleavage form of PARP, was increased at the higher concentrations of  $H_2O_2$  (Fig. 3, lower bands).

These results suggest that ROS treatment of over  $300 \,\mu\text{M}$  of H<sub>2</sub>O<sub>2</sub>, will arrest the cell cycle, with the cells then falling into apoptosis in the SNU-C2A cell line. As a result, the SNU-C2A proliferation rate significantly decreased when treated with 600 or 900  $\mu\text{M}$  of H<sub>2</sub>O<sub>2</sub>.

JNK signaling pathway regulates the expression level of LGR5 by ROS. To investigate whether ROS affected expression of a cancer stem cell marker, we examined LGR5 expression level after  $H_2O_2$  treatment of SNU-C2A cells for 24 h, by using RT-PCR, western blotting, and immunocytochemical staining (Figs. 4 and 5A).

To clarify the effect of ROS in these cells, we assessed the expression level of HO-1, which is induced by various stimuli and is known to play a significant role in protection of cells against oxidative injury, heat shock, and ROS. In addition, HO-1 may be involved in anti-apoptotic activity through activation of the Akt pathway (21). We detected overexpression of HO-1 at treatment of 100-300 µM H<sub>2</sub>O<sub>2</sub> in SNU-C2A cells (Fig. 4). We also investigated jun expression, considered to be another indicator that affected by ROS. The expression pattern of jun, a JNK signaling pathway component, was similar to HO-1. Jun expression resulted from activation of the JNK signaling pathway, which is also involved in H<sub>2</sub>O<sub>2</sub> induced upregulation of HO-1 (22). When jun is activated by phosphorylation, the JNK signaling pathway is stimulated (23). Here, phospho-jun increased in a dose-dependent manner with H<sub>2</sub>O<sub>2</sub> treatment (Fig. 4B), indicating that JNK signaling is activated by  $H_2O_2$ . Our results support previous MTT results (Fig. 2) and suggest that JNK signaling has a protective effect against ROS (22). In addition, the result indicate that ROS induce cell proliferation through upregulation of jun and via cross-talk with the PI3-K/ PKB pathway (24). Furthermore, a recent study has shown that



Figure 4. Induction of  $\beta$ -catenin and LGR5 expression following treatment with  $H_2O_2$ . (A), RT-PCR was performed after treatment with  $H_2O_2$ . SNU-C2A cancer cells were treated with 50, 100, 150, 300, 600, or 900  $\mu$ M of  $H_2O_2$  and mRNA expressions of LGR5,  $\beta$ -catenin, and HO-1 were assessed. Each sample was normalized by  $\beta$ -actin level. (B), Protein levels determined by western blotting after treatment with  $H_2O_2$ . In each lane, 20  $\mu$ g of protein was loaded.

LGR5 is a novel target of c-jun/Mbd3 (25). Based on our results, we can confirm a similar expression pattern in LGR5 and jun, leading to the suggestion that activation of JNK signaling is associated with alteration of LGR5 expression by ROS.

Induction of  $\beta$ -catenin and LGR5 as treated with  $H_2O_2$ . LGR5 expression increased following cell treatment with 50-300  $\mu$ M of  $H_2O_2$ ; a finding that is similar to the proliferation increase noted in Fig. 2. In contrast, LGR5 expression decreased at doses higher than 600  $\mu$ M of  $H_2O_2$ , which were the same level at which apoptosis was induced (Figs. 4 and 5A).

Since LGR5 is a Wnt target gene (2,14,15), we analyzed the correlation between LGR5 and  $\beta$ -catenin, a Wnt signaling component. As shown in Fig. 4, the expression level of  $\beta$ -catenin increased with H<sub>2</sub>O<sub>2</sub> treatment in a dose-dependent manner. Immunocytochemistry was performed in SNU-C2A cells that were treated with the same dosage levels of H<sub>2</sub>O<sub>2</sub> as shown in Fig. 4 (Fig. 5). The expression patterns of LGR5 and  $\beta$ -catenin were found to be similar (Fig. 4).

To determine whether induction of LGR5 is the result of  $\beta$ -catenin-mediated Wnt signaling, the location of  $\beta$ -catenin within the cells was determined. As shown in Fig. 5,  $\beta$ -catenin was mainly present in the cytoplasm. To confirm the immuno-cytochemistry results, we separated and isolated cytoplasmic and nuclear proteins, and performed western blotting. The  $\beta$ -catenin levels were lower in the nucleus of H<sub>2</sub>O<sub>2</sub>-treated cells than in the cytoplasm (Fig. 6). For activation of  $\beta$ -catenin-



Figure 5. Immunostaining of LGR5 and  $\beta$ -catenin. SNU-C2A cancer cells were treated with H<sub>2</sub>O<sub>2</sub> for 24 h. LGR5 (A) and  $\beta$ -catenin (B) expression levels were detected by staining FITC-conjugated antibody and nucleus by DAPI (100  $\mu$ g/ml).



Figure 6. The expression pattern of  $\beta$ -catenin. After treatment of H<sub>2</sub>O<sub>2</sub>, protein was extracted separately from cytoplasm and nucleus. HSP60 is a mitochondrial chaperon protein that expressed in cytoplasm. Lamin B is an intermediate filament that provides structural function and transcriptional regulation in the cell nucleus (C, SNU-C2A; H, SNU-C2A treated with 150  $\mu$ M of H<sub>2</sub>O<sub>2</sub> for 24 h).



Figure 7. Co-immunoprecipitation of LGR5. For co-immunoprecipitation of LGR5, SNU-C2A lysates that were treated with  $H_2O_2$  were prepared.  $\beta$ -catenin was not detected by western blotting in the immunoprecipitate with LGR5 (WB, western blotting; C, SNU-C2A; H, SNU-C2A treated with 150  $\mu$ M of

mediated Wnt signaling, stabilized  $\beta$ -catenin needs to be translocated to the nucleus and not degraded in the cytoplasm. Our results show that nuclear  $\beta$ -catenin levels were low; therefore, the expression of LGR5 could be regulated by factors other than those in Wnt signaling.

To investigate this, we performed co-immunoprecipitation to determine if LGR5 directly interacts with  $\beta$ -catenin. Western blotting with anti- $\beta$ -catenin was used to analyze the co-immunoprecipitation obtained by using the LGR5 antibody. As shown in Fig. 7,  $\beta$ -catenin was not detected. Therefore, we concluded that LGR5 did not interact with  $\beta$ -catenin.

### Discussion

H<sub>2</sub>O<sub>2</sub> for 24 h).

LGR5 (GPR49) has been identified as a marker of tumor initiation (2). The LGR5 gene encodes a G protein coupled receptor that is associated with a glycoprotein ligand. LGR5 gene marks small cells, especially cycling crypt-base columnar (CBC) cells that are interspersed between Paneth cells (1). Moreover, physiological expression of LGR5 is restricted to cells at the base of crypts, a location known as a stem cell niche. LGR5 is one of the Wnt signaling target genes in colorectal cancer and is critically involved in the development of carcinoma associated with  $\beta$ -catenin mutation (14,15). Wnt signaling regulates intestinal epithelium cell lineage proliferation, differentiation, and maintenance (26). When mutated, such as APC mutation, the Wnt signaling pathway is activated, and it plays a role in tumorigenesis in humans (26). Therefore, it has been suggested that activation of Wnt signaling and expression of Wnt target genes are involved in tumor initiation (27).

In our study, high expression of LGR5 was observed in 90.6% the human colon cancer cell lines tested (Fig. 1). However, in a few cell lines, including SNU-C2A, the LGR5 expression level was low. In order to examine the effect of ROS on colorectal cancer cells and on the cancer stem cell marker LGR5, experiments with the treatment of the H<sub>2</sub>O<sub>2</sub> were perform.  $H_2O_2$  is reported to regulate the intensity of growth factor signaling, metabolism, aging and apoptosis (28). In addition, it acts as either a negative or positive regulator in the Wnt signaling pathway. Shin et al have shown that H<sub>2</sub>O<sub>2</sub> can inhibit What signaling through the down-regulation of  $\beta$ -catenin (16). In contrast, Funato et al showed that treatment of cells with a low dose of  $H_2O_2$  induces stabilization of  $\beta$ -catenin and increased expression of endogenous Wnt target genes (17). Even in our results, the effects of H<sub>2</sub>O<sub>2</sub> on Wnt signaling and a target gene were not clear. However, based on such findings, LGR5 expression is expected to be affected by  $H_2O_2$ .

In our study, SNU-C2A colon cancer cells, which have wild-type  $\beta$ -catenin (17) and a low expression of LGR5, were used to determine the correlation between ROS and LGR5.

To that end, SNU-C2A cells were treated with 50, 100, 150, 300, 600, or 900  $\mu$ M of H<sub>2</sub>O<sub>2</sub> for 24 h to examine the ROS effects. According to Park et al, low doses of H<sub>2</sub>O<sub>2</sub> resulted in enhanced cell proliferation accompanied by an increase in COX-2 expression, whereas apoptosis was induced by high doses of  $H_2O_2$  and was correlated with AMPK activation (19,29). There were similarities in our results. As shown in Fig. 2A, the number of SNU-C2A cells increased to a greater extent when treated with low doses of H<sub>2</sub>O<sub>2</sub>, indicating that cell proliferation increased with low dose treatment of H2O2; however, there was no statistical significance to the difference. With high doses of H<sub>2</sub>O<sub>2</sub>, however, cell viability significantly decreased with increased cell death with treatment of 600 and 900  $\mu$ M of H<sub>2</sub>O<sub>2</sub>. As cell proliferation changed with different H<sub>2</sub>O<sub>2</sub> dosage, we performed cell cycle analysis using the same dosages of ROS. As shown in Fig. 2B, the percentage of cells in the G1 stage increased following treatment with 50-300  $\mu$ M H<sub>2</sub>O<sub>2</sub>. At higher H<sub>2</sub>O<sub>2</sub> concentrations percentage of the cells in the G2/M phase decreased and those in the subG1 phase increased. The results indicate that, at low levels of H<sub>2</sub>O<sub>2</sub> treatment, the cell cycle is arrested at the G1 phase to evade cell death. However, at the higher H<sub>2</sub>O<sub>2</sub> dosage the increase in the subG1 stage is mediated through apoptotic cell death, which we confirmed through assessment of the amount of PARP cleavage (Fig. 3, lower bands).

We also investigated whether  $H_2O_2$  affects expression of LGR5. Expression of HO-1 was induced in  $H_2O_2$ -treated SNU-C2A in a dose-dependent manner (Fig. 4). The HO-1 is involved in heme catabolism and plays an anti-apoptotic role against various stimuli, including those related to ROS and heat shock (21). Therefore, our result suggest that an increase in HO-1 would indicate that H2O2 is a potent inducer of cellular responses to ROS and that HO-1 was expressed in order to reduce oxidative stress in the treated SNU-C2A cells. JNK signaling, related to the promotion of cell survival, was also induced by  $H_2O_2$  treatment (22). Following  $H_2O_2$  treatment, the expression of jun, a JNK signaling component, increased in a pattern similar to that of HO-1 (Fig. 4). This result suggests that an increase in jun expression can be regulated by the cellular ROS level; thus, aiding in the prevention of cell death, as was mentioned for HO-1. The LGR5 expression level significantly increased following low dose treatment of H2O2 in colon cancer cells. A recent study showed that LGR5 is a novel target of c-jun/Mbd3 (25), and our results confirm a correlative pattern between LGR5 and jun expression, leading to the suggestion that activation of JNK signaling by ROS is associated with LGR5 expression.

In conclusion, induced HO-1 and jun expression by H<sub>2</sub>O<sub>2</sub> treatment results in a reduction of cellular ROS; thereby, LGR5 expression is increased. According to these results, LGR5 is one of the stress induced genes. Since LGR5 is a Wnt target gene (2,14,15), we supposed that LGR5 expression increases through  $H_2O_2$  activation of  $\beta$ -catenin-mediated Wnt signaling. Fig. 4 shows that  $\beta$ -catenin expression levels, associated with the Wnt signaling pathway, also increased in H<sub>2</sub>O<sub>2</sub>-treated colon cancer cells in a dose-dependent manner. However, an increased level of  $\beta$ -catenin was detected only in cytoplasm, not in the nucleus (Figs. 5 and 6). As a result, Wnt signaling would not be involved in H<sub>2</sub>O<sub>2</sub>-mediated expression of LGR5; thus, further investigation is needed. Cross-talk between JNK and Wnt signaling has been reported (30) and we speculated that there could be a correlation between  $\beta$ -catenin and jun. However, nuclear  $\beta$ -catenin, which acts as a Wnt signaling transcriptional factor, was not detected. Therefore, there was no relevance to the association between JNK and Wnt signaling. Since induction of LGR5 seemed not to be regulated by Wnt signaling, we performed co-immunoprecipitation in order to determine if LGR5 directly interacts with  $\beta$ -catenin (Fig. 7). However, we detected no direct interaction between LGR5 and β-catenin.

In this study, we demonstrated that LGR5 and  $\beta$ -catenin expression in colorectal cancer cells is increased by H<sub>2</sub>O<sub>2</sub> treatment. However, there remain questions as to why the expression levels of LGR5 and  $\beta$ -catenin increased at the same time and what their relative functions may be. In order to answer these questions, further study is necessary; we expect that our data will be fundamental to such a study.

## Acknowledgements

This work was supported by Mid-career Researcher Program (MEST R01-2008-000-20108-0) and Priority Research Centers Program (2009-0093820) through National Research Foundation of Korea grant funded by the MEST Ministry of Educational Science and Technology.

#### References

 Barker N and Clevers H: Tracking down the stem cells of the intestine: strategies to identify adult stem cells. Gastroenterology 133: 1755-1760, 2007.

- Barker N, van Es JH, Kuipers J, *et al*: Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449: 1003-1007, 2007.
- Becker L, Huang Q and Mashimo H: Immunostaining of Lgr5, an intestinal stem cell marker, in normal and premalignant human gastrointestinal tissue. Sci World J 8: 1168-1176, 2008.
- Barker N and Clevers H: Leucine-rich repeat-containing G-proteincoupled receptors as markers of adult stem cells. Gastroenterology 138: 1681-1696, 2010.
- Dalerba P, Cho RW and Clarke MF: Cancer stem cells: models and concepts. Annu Rev Med 58: 267-284, 2007.
- Ricci-Vitiani L, Lombardi DG, Pilozzi E, *et al*: Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115, 2007.
- Corbeil D, Röper K, Hellwig A, *et al*: The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 275: 5512-5520, 2000.
- 8. Burkert J, Wright NA and Alison MR: Stem cells and cancer: an intimate relationship. J Pathol 209: 287-297, 2006.
- Bao S, Wu Q, McLendon RE, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760, 2006.
- Li X, Lewis MT, Huang J, *et al*: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100: 672-679, 2008.
- Phillips TM, McBride WH and Pajonk F: The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98: 1777-1785, 2006.
- Diehn M, Cho RW, Lobo NA, *et al*: Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458: 780-783, 2009.
- Fridovich I: The biology of oxygen radicals. Science 201: 875-880, 1978.
- Yamamoto Y, Sakamoto M, Fujii G, *et al*: Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with beta-catenin mutations. Hepatology 37: 528-533, 2003.
- Fan XS, Wu HY, Yu HP, Zhou Q, Zhang YF and Huang Q: Expression of Lgr5 in human colorectal carcinogenesis and its potential correlation with beta-catenin. Int J Colorectal Dis 25: 583-590, 2010.
- Shin SY, Kim CG, Jho EH, *et al*: Hydrogen peroxide negatively modulates Wnt signaling through downregulation of beta-catenin. Cancer Lett 212: 225-231, 2004.
- Funato Y, Michiue T, Asashima M and Miki H: The thioredoxin-related redox-regulating protein nucleoredoxin inhibits Wnt-beta-catenin signalling through dishevelled. Nat Cell Biol 8: 501-508, 2006.

- Oh JH, Ku JL, Yoon KA, *et al*: Establishment and characterization of 12 human colorectal-carcinoma cell lines. Int J Cancer 81: 902-910, 1999.
- Park IJ, Hwang JT, Kim YM, Ha J and Park OJ: Differential modulation of AMPK signaling pathways by low or high levels of exogenous reactive oxygen species in colon cancer cells. Ann NY Acad Sci 1091: 102-109, 2006.
- Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S and Smulson M: Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. J Biol Chem 274: 22932-22940, 1999.
- Busserolles J, Megias J, Terencio MC and Alcaraz MJ: Heme oxygenase-1 inhibits apoptosis in Caco-2 cells via activation of Akt pathway. Int J Biochem Cell Biol 38: 1510-1517, 2006.
- Aggeli IK, Gaitanaki C and Beis I: Involvement of JNKs and p38- MAPK/MSK1 pathways in H<sub>2</sub>O<sub>2</sub>-induced upregulation of heme oxygenase-1 mRNA in H9c2 cells. Cell Signal 18: 1801-1812, 2006.
- Myatt SS, Brosens JJ and Lam EW: Sense and sensitivity: FOXO and ROS in cancer development and treatment. Antioxid Redox Signal 14: 675-687, 2011.
- 24. Liu SL, Lin X, Shi DY, Cheng J, Wu CQ and Zhang YD: Reactive oxygen species stimulated human hepatoma cell proliferation via cross-talk between PI3-K/PKB and JNK signaling pathways. Arch Biochem Biophys 406: 173-182, 2002.
- Aguilera C, Nakagawa K, Sancho R, Chakraborty A, Hendrich B and Behrens A: c-Jun N-terminal phosphorylation antagonises recruitment of the Mbd3/NuRD repressor complex. Nature 469: 231-235, 2011.
- Reya T and Clevers H: Wnt signalling in stem cells and cancer. Nature 434: 843-850, 2005.
- 27. Zeilstra J, Joosten SP, Dokter M, Verwiel E, Spaargaren M and Pals ST: Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res 68: 3655-3661, 2008.
- Giorgio M, Trinei M, Migliaccio E and Pelicci PG: Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals? Nat Rev Mol Cell Biol 8: 722-728, 2007.
- Lee YK, Lee MS, Kim YM and Park OJ: Effects of cotreatment of 12-O-tetradecanoylphorbol-13-acetate and H<sub>2</sub>O<sub>2</sub> on apoptotic regulation via AMP-activated protein kinase-cyclooxygenase-2 signals. Ann NY Acad Sci 1171: 564-569, 2009.
- Sancho R, Nateri AS, De Vinuesa AG, et al: JNK signalling modulates intestinal homeostasis and tumourigenesis in mice. EMBO J 28: 1843-1854, 2009.